Want to see MLYS full AI Analyst Report?
MLYS Stock Chart & Stats
$26.71
-$0.29(-1.07%)
At close: 4:00 PM EDT
$26.71
-$0.29(-1.07%)
Day’s Range― - ―
52-Week Range$14.53 - $47.65
Previous CloseN/A
Volume648.86K
Average Volume (3M)1.31M
Market Cap
$2.27B
Enterprise Value$1.72K
Total Cash (Recent Filing)$661.41M
Total Debt (Recent Filing)$97.62M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Nov 16, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.24
Shares Outstanding88,406,880
10 Day Avg. Volume629,633
30 Day Avg. Volume1,308,886
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)3.80
Price to Sales (P/S)0.00
P/FCF Ratio-17.24
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.08
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.00Price Target Upside90.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Biomarker DifferentiationConsistent blood-pressure efficacy plus a meaningful albuminuria signal could differentiate lorundrostat in cardiorenal disease. If confirmed through regulatory review and use, the broader biological profile may support adoption beyond hypertension.
Regulatory And Commercial Launch ReadinessAn active regulatory review and established commercial infrastructure reduce execution risk if approval is granted. Early payer and prescriber engagement may support faster market access and adoption after launch.
Control Of Asset Economics And Funding RunwayRemoving future royalties improves the potential long-term economics of the lead asset, while substantial liquidity supports continued development and launch investment. Together, these actions increase control over value capture.
Bears Say
Pre-revenue Model And Widening LossesWithout product revenue, Mineralys remains dependent on successful clinical development and eventual approval to establish an operating model. Widening losses also indicate that commercialization will require substantial spending before meaningful earnings can emerge.
Persistent Cash Burn And External Funding DependenceMaterial recurring cash outflows limit financial flexibility and make the company sensitive to development delays, approval setbacks or weaker launch economics. Even with available liquidity, continued burn may require additional financing over time.
Debt, Milestone And Reimbursement Execution RiskNew secured debt and milestone obligations increase fixed cash commitments and could constrain operations if approval or sales milestones are delayed. Unfinalized pricing and restricted initial Medicare access may also slow broad commercial uptake.
Mineralys Therapeutics, Inc. News
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $14.53 and its highest was $47.65 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $2.27B.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 83 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$2.85 earnings per share for the quarter, missing the consensus estimate of -$0.549 by -$2.301.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 88,406,880 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$2.85 in its last earnings report, missing expectations of -$0.549. Following the earnings report the stock price went down -1.025%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mineralys Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.00 (90.94% Upside)
$51.00 (90.94% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
87.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
98.93%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
MLYS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong clinical data, regulatory progress toward a December 22, 2026 PDUFA, significant commercial launch preparation, and strategic actions (royalty repurchase and financing) intended to enhance long-term value and provide runway into 2028. These positive, strategic developments were tempered by materially higher near‑term expenses and a widened quarterly net loss driven largely by a one-time $200 million upfront payment and increased commercial hiring and professional fees. Management framed the elevated costs as deliberate investments to support launch readiness and future value capture.View all MLYS earnings summariesMLYS Stock 12 Month Forecast
Average Price Target
$51.00
▲(90.94% Upside)
Technical Analysis
Ownership Overview
25.36% Insiders
17.08% Mutual Funds
24.20% Other Institutional Investors
21.61% Public Companies and
Individual Investors